Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Tu

Showing results (311-320 of 321) with videos related to

Pageof 33
Sort By:
Targeted Oncology|January 12, 2022
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in ChinaHai-Yan Tu, Jifeng Feng, Meiqi Shi, et al.
JAMA Oncology|June 13, 2024
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSong Dong, Zhen Wang, Jia-Tao Zhang, et al.
Cancer Cell|October 10, 2023
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patientsYi Pan, Jia-Tao Zhang, Xuan Gao, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2021
Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73]Sebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.
Cell Reports|August 8, 2024
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLCYang-Si Li, Wen-Pu Lai, Kai Yin, et al.
Nature Medicine|July 24, 2023
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSi-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastasesYang-Si Li, Wenpu Lai, Kai Yin, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusionsSebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.
Nature Medicine|February 27, 2025
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastasesMei-Mei Zheng, Qing Zhou, Hua-Jun Chen, et al.
Cancer Discovery|March 28, 2020
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung CancersBob T Li, Flavia Michelini, Sandra Misale, et al.
Pageof 33

Showing results (311-320 of 321) with videos related to

Sort By:
Pageof 33
Targeted Oncology|January 12, 2022
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in ChinaHai-Yan Tu, Jifeng Feng, Meiqi Shi, et al.
JAMA Oncology|June 13, 2024
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSong Dong, Zhen Wang, Jia-Tao Zhang, et al.
Cancer Cell|October 10, 2023
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patientsYi Pan, Jia-Tao Zhang, Xuan Gao, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2021
Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73]Sebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.
Cell Reports|August 8, 2024
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLCYang-Si Li, Wen-Pu Lai, Kai Yin, et al.
Nature Medicine|July 24, 2023
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSi-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastasesYang-Si Li, Wenpu Lai, Kai Yin, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusionsSebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.
Nature Medicine|February 27, 2025
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastasesMei-Mei Zheng, Qing Zhou, Hua-Jun Chen, et al.
Cancer Discovery|March 28, 2020
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung CancersBob T Li, Flavia Michelini, Sandra Misale, et al.
Pageof 33